Injective (INJ) is currently trading at $6.19, reflecting a 2.67% increase over the last 24 hours. The daily trading range has been relatively tight, with a high of $6.29 and a low of $5.92, indicating stability in the short term.

Volume over the last 24 hours stands at approximately 82.15 million, representing 13.29% of its market cap. This volume is significant, suggesting robust trading activity and interest in the asset as it approaches its resistance levels.

The short-term moving averages indicate a bullish trend, with the 8 SMA at $6.04 showing a gain of 2.45%, and the 13 SMA slightly higher at $6.03 with a 2.73% increase. The longer moving averages, such as the 144 SMA at $5.65, are also trending positively, reflecting a potential upward momentum in the medium term.

The 1-hour RSI is at 77, indicating that INJ may be overbought in the very short term. However, the 7-day RSI of 55 suggests a more neutral position, providing room for upward movement without immediate bearish pressure.

Over the past week, INJ has gained approximately 1.52%, while the 14-day and 30-day metrics show declines of -9.07% and -25.81%, respectively, indicating a recovery from recent lows. The current price remains significantly below its all-time high of $52.62, achieved in March 2024, which indicates considerable potential for growth as market conditions improve.

Given the current technical indicators, including bullish moving averages and a healthy trading volume, the outlook for INJ is positive in the short to medium term. However, the high 1-hour RSI suggests caution for immediate buying.

Based on this analysis, I would rate Injective (INJ) as a Hold, recommending monitoring for further confirmation of upward momentum before considering new positions.